ClinicalTrials.gg
RecruitingNCT07439471Updated Nov 9, 2026

Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance

An observational study in Cigarette Smoking-Related Carcinoma, sponsored by Roswell Park Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Roswell Park Cancer Institute · Observational

How we know

Updated Nov 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 371 studies in Cigarette Smoking with a site in United States — 68 open to participants now, 75 under way, 3 of them phase 3. Cigarette Smoking · United States.

Planned enrollment
25th of 30
40 · median 159
Started
2026
with 18 others
Observational
30 of 371
6 open now
Primary completion
2027-03
later than 28 of 74 live
Registered
355th of 371
by date

Among the 371 studies in Cigarette Smoking with a site in United States, this one is the 25th largest by planned enrollment of the 30 observational ones that give a count, is one of 19 that started in 2026, is one of 30 observational ones, reaches primary completion later than 28 of the 74 other live ones, and was the 355th registered.

Cigarette Smoking

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

Browse Cigarette Smoking studies →

Open to participants now

68 of the 371 studies in Cigarette Smoking with a site in United States are open now. Recruiting first, the newest first:

62 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 371 studies in Cigarette Smoking with a site in United States, or all of them as a file.
02

Study summary

This study evaluates histories among cannabis and tobacco co-users of their initiation, escalation, and maintenance of the co-use behavior.

Read the detailed description

PRIMARY OBJECTIVE:

I. To generate detailed thematic analysis of structured interviews to provide insights into individual historical factors, social contextual factors, and product-level factors that contribute to the co-use of nicotine/tobacco and cannabis products.

OUTLINE: This is an observational study.

Participants complete an interview and survey on study.

03

Conditions studied

  • Cigarette Smoking-Related Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult cannabis users who also use cigarettes or nicotine vaping products.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • * Adults aged 18 to 30 years old.

    • Currently living in the Roswell Park catchment area.
    • Able to speak, read, and write in English.
    • Currently consuming cannabis at least weekly.

      • Group 1: currently using cigarettes daily and not using nicotine vaping products more than one day per week.
      • Group 2: currently using nicotine vaping products daily and not using cigarettes more than one day per week.

Exclusion criteria

Exclusion Criteria:

  • * Unwilling or unable to follow protocol requirements.

    • Individuals under the age of 18 or over 30.
    • Individuals not meeting product consumption criteria for inclusion items 3 and 4.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)

Groups and cohorts

  • Observational

    Participants complete an interview and survey on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. thematic analysis of individual narratives on nicotine and cannabis

    Structured interview sessions

    Time frame: Reported at baseline

Secondary outcomes

  1. Insight into the Social contexts of use and co-use of nictotine and cannabis

    Structured interview session on escalation of use

    Time frame: reported at baseline

  2. Insight into Current practices of tobacco/cannabis use

    Structured interview session on maintenance of use

    Time frame: reported at baseline

  3. Insights into factors that contribute to the co-use of nicotine/tobacco and cannabis products

    Structured interview sessions on history of use

    Time frame: reported at baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartEst.
Dec 28, 2026was Sep 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 28, 2026→Dec 28, 2026
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Sep 28, 2026→Dec 28, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07439471
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Dec 28, 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Connor Martin
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion